Introduction: The recent failure of several clinical trials on anti-Î²-amyloid (AÎ²) drugs in Alzheimerâs disease (AD) suggested earlier intervention in the disease course. Secondary prevention trials have been started in autosomal-dominant AD (ADAD) individuals without cognitive dysfunction and in cognitively healthy subjects at risk of developing sporadic AD (SAD). Areas covered: Herein, the authors discuss prevention trials in ADAD and SAD, with a focus on the anti-AÎ² monoclonal antibodies solanezumab and gantenerumab presently in Phase III clinical development. These therapies are also being tested in the Dominantly Inherited Alzheimerâs Network Trials Unit (DIAN-TU). Expert opinion: Anti-AÎ² monoclonal antibodies are being tested in subjects at the preclinical stage of ADAD and even in symptom-free subjects at risk of developing SAD. The subsequent DIAN-TU Adaptive Prevention Trial is a 4-year study that will assess whether such biomarker effects may stop the progress of the AD process, preventing cognitive symptoms. The hope is to interfere in the disease course when it is not too late. A clinical success of these prevention trials would represent the proof of the AÎ² hypothesis of AD.
|Titolo:||The potential of solanezumab and gantenerumab to prevent Alzheimerâs disease in people with inherited mutations that cause its early onset|
|Data di pubblicazione:||2018|
|Appare nelle tipologie:||1.1 Articolo in rivista|